Expansion of Biologics CDMO & Manufacturing Capacity Offerings at Paras Biopharmaceuticals Finland

29 March 2022 | Tuesday | News

Paras Biopharmaceuticals Finland Oy is pleased to announce that from Q3-2022, the company will be in a position to offer an expanded and increased biologics CDMO capacity to biopharmaceutical companies within Europe, USA and Canada. Increased capacity offering comes in the form of expanded production timeslots becoming available due to a successful earlier-than-expected conclusion of a previous biologics and biosimilar product development.
Image Source : Public Domain

Image Source : Public Domain

Due to the company’s technologies, its deep scientific knowhow and the specialized skills of the Paras Biopharma team, all of Paras Biopharmaceutical’s project milestones were completed ahead of time.

Paras Biopharma scale-up batches capacities and offerings will be multiple batches/clients at 20L / 150L / 750L scale.

“With the Paras Biopharma teams’ continuous strive to work on innovative and challenging projects from clients in the USA and Europe, the main focus on the team is quality and full commitment”, says Dr Mark Jackson: Administration Lead and Business Development Associate.

“Increased capacity offerings will allow Paras Biopharma to undertake new client projects and to deliver then successfully. This will further add to our satisfaction that the company is able to contribute to the field of biologics development and innovation with our biologics manufacturing”, adds Dr Ashesh Kumar, CEO.


Should any company or Development Production group have a need for manufacturing productions slots in Q3 2022 onwards,

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in